Suppr超能文献

美国肿瘤学家对临床试验目的的看法。

Views of American oncologists about the purposes of clinical trials.

作者信息

Joffe Steven, Weeks Jane C

机构信息

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

出版信息

J Natl Cancer Inst. 2002 Dec 18;94(24):1847-53. doi: 10.1093/jnci/94.24.1847.

Abstract

BACKGROUND

Many research subjects believe incorrectly that the primary purpose of clinical trials is to benefit the participants rather than to improve therapy for future patients. However, few data are available about how physicians view trials.

METHODS

We mailed surveys to a stratified random sample (n = 1120) of U.S. medical, pediatric, and other oncology specialists who were selected from the American Society of Clinical Oncology Membership Directory. Respondents were asked to select, from a list of options, their reasons for enrolling individual patients in trials and what they thought the main societal purposes of clinical trials are. We used logistic regression models to evaluate which demographic and clinical practice characteristics were associated with responses to these questions. All statistical tests were two-sided.

RESULTS

Of the 547 physicians (48.8%) who responded, 40.5% of the medical oncologists, 32.3% of the pediatric oncologists, and 62.6% of the other oncology subspecialists reported enrolling individual patients in clinical trials to improve future therapy. Most of the other respondents reported enrolling patients to ensure that they received state-of-the-art treatment. When asked about the main societal purpose of clinical trials, 72.7% of the medical oncologists, 59.4% of the pediatric oncologists, and 81.9% of the other oncology subspecialists cited improving future therapy; most of the other respondents cited ensuring state-of-the-art treatment for participants. In multivariable analysis, medical oncologists (odds ratio [OR] = 0.6, 95% confidence interval [CI] = 0.3 to 0.9) and pediatric oncologists (OR = 0.3, 95% CI = 0.2 to 0.5) were less likely than other oncologists to identify improving future therapy as the main societal purpose of clinical trials, whereas industry physicians (OR = 4.6, 95% CI = 1.1 to 20.5) chose this option more often than physicians who did not work for industry.

CONCLUSIONS

Many respondents viewed the main societal purpose of clinical trials as benefiting the participants rather than as creating generalizable knowledge to advance future therapy. This view, which was more prevalent among specialists such as pediatric oncologists that enrolled greater proportions of patients in trials, conflicts with established principles of research ethics.

摘要

背景

许多研究对象错误地认为,临床试验的主要目的是使参与者受益,而非改善未来患者的治疗。然而,关于医生如何看待试验的数据却很少。

方法

我们向从美国临床肿瘤学会会员名录中选取的美国医学、儿科及其他肿瘤学专家的分层随机样本(n = 1120)邮寄了调查问卷。要求受访者从一系列选项中选出他们将个体患者纳入试验的原因,以及他们认为临床试验的主要社会目的是什么。我们使用逻辑回归模型来评估哪些人口统计学和临床实践特征与对这些问题的回答相关。所有统计检验均为双侧检验。

结果

在回复的547名医生(48.8%)中,40.5%的医学肿瘤学家、32.3%的儿科肿瘤学家以及62.6%的其他肿瘤学亚专科医生报告称,将个体患者纳入临床试验是为了改善未来的治疗。其他大多数受访者报告称将患者纳入试验是为了确保他们接受最先进的治疗。当被问及临床试验的主要社会目的时,72.7%的医学肿瘤学家、59.4%的儿科肿瘤学家以及81.9%的其他肿瘤学亚专科医生提到改善未来治疗;其他大多数受访者提到确保为参与者提供最先进的治疗。在多变量分析中,医学肿瘤学家(优势比[OR] = 0.6,95%置信区间[CI] = 0.3至0.9)和儿科肿瘤学家(OR = 0.3,95% CI = 0.2至0.5)比其他肿瘤学家更不太可能将改善未来治疗视为临床试验的主要社会目的,而行业医生(OR = 4.6,95% CI = 1.1至20.5)比非行业医生更常选择这一选项。

结论

许多受访者认为临床试验的主要社会目的是使参与者受益,而非创造可推广的知识以推进未来治疗。这种观点在儿科肿瘤学家等在试验中纳入患者比例更高的专科医生中更为普遍,这与既定的研究伦理原则相冲突。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验